BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19304406)

  • 1. Mucositis versus tumor control: the therapeutic index of adding chemotherapy to irradiation of head and neck cancer.
    Lee IH; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1060-3. PubMed ID: 19304406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How much radiation is the chemotherapy worth in advanced head and neck cancer?
    Kasibhatla M; Kirkpatrick JP; Brizel DM
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1491-5. PubMed ID: 17674979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma.
    Rosenthal DI; Ang KK
    Semin Radiat Oncol; 2004 Apr; 14(2):153-66. PubMed ID: 15095261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Hartley A; Sanghera P; Glaholm J; Mehanna H; McConkey C; Fowler J
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):125-30. PubMed ID: 19880297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunoglobulin for prevention of radiogenic mucositis].
    Mose S; Adamietz IA; Thilmann C; Saran F; Heyd R; Knecht R; Böttcher HD
    HNO; 1995 Jul; 43(7):421-6. PubMed ID: 7672999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
    Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head and neck squamous cell carcinoma: optimizing the therapeutic index.
    Rosenthal DI; Blanco AI
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):501-14. PubMed ID: 16001957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
    Budach W; Hehr T; Budach V; Belka C; Dietz K
    BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
    Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
    Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
    Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies.
    Elting LS; Cooksley CD; Chambers MS; Garden AS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1110-20. PubMed ID: 17398022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
    Bernier J; Cooper JS; Pajak TF; van Glabbeke M; Bourhis J; Forastiere A; Ozsahin EM; Jacobs JR; Jassem J; Ang KK; Lefèbvre JL
    Head Neck; 2005 Oct; 27(10):843-50. PubMed ID: 16161069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.